Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Midwest · Wisconsin
Local context for Wegovy, Ozempic, Mounjaro, and Zepbound in Milwaukee (560,000 residents, 1,560,000 metro). BadgerCare Plus covers T2D GLP-1s with prior auth; Wisconsin has not adopted full ACA expansion but extends coverage up to 100% FPL.
Availability and prices vary by pharmacy and date. We do not maintain real-time per-pharmacy stock data. Confirm with pharmacies directly.
Wegovy
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for chronic weight management in adults and adolescents.
Wegovy in Milwaukee →
Ozempic
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for adults with type 2 diabetes.
Ozempic in Milwaukee →
Mounjaro
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for adults with type 2 diabetes.
Mounjaro in Milwaukee →
Zepbound
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for chronic weight management and obstructive sleep apnea.
Zepbound in Milwaukee →
Milwaukee is a midwest-region city with a population of 560,000 (1,560,000 in the broader metropolitan area). Wisconsin has not expanded Medicaid under the Affordable Care Act, which limits low-income adults' access to GLP-1 coverage; many uninsured residents rely on manufacturer savings programs or compounded options instead.
Statewide, notable health systems include UW Health, Aurora Health Care, Froedtert Health.
Wisconsin's Medicaid program is BadgerCare Plus / Wisconsin Medicaid. Coverage rules for GLP-1 medications vary by drug and indication; see our pricing by state map and payer-coverage guides for details.
Cities of similar size with comparable healthcare markets.